Abstracts Archive - Page 563 of 2607 - ACR Meeting Abstracts

Abstract Number: 1199 • ACR Convergence 2022
Validation of New Medication User Definitions in Single-Specialty EHR Data
Jeffrey Curtis¹, Yujie Su², Michael george³, Cassie Clinton², Patrick Stewart⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³UPENN, Philadelphia, PA, ⁴Bendcare, Boca Raton, FL, ⁵FASTER, Hoover, AL
Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…
Abstract Number: 1198 • ACR Convergence 2022
Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Bradley Pearce¹, S. Sam Lim¹, Cristina Drenkard¹ and Laura Plantinga¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: The disruption of the COVID-19 pandemic presented an opportunity for researchers to develop and administer remote versions of measures for ongoing studies. In an…
Abstract Number: 1197 • ACR Convergence 2022
Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank
Ruth Topless¹, Ralph Green², Sarah L Morgan³, Philip Robinson⁴, Tony Merriman¹ and Angelo Gaffo³, ¹University of Otago, Dunedin, New Zealand, ²Departments of Pathology and Medicine, University of California Davis at Sacramento, Sacramento, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴School of Clinical Medicine, University of Queensland, Brisbane, Australia
Background/Purpose: Folate metabolism is implicated in SARS-CoV-2 infectivity. The current study seeks to determine if methotrexate (an antifolate) or folic acid prescription were associated with…
Abstract Number: 1191 • ACR Convergence 2022
The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study
HSIN-HUA CHEN¹ and Tsai-Hung Yen², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of General Medicine, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: The pathologic hallmarks of systemic sclerosis (SSc) included a non-inflammatory obliterative vasculopathy affecting small arteries and arterioles in multiple vascular beds. Whether macrovascular involvement…
Abstract Number: 1203 • ACR Convergence 2022
The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis
Jenna Lanz¹, Jan Hughes-Austin², Anna Podolanczuk³, John Kim⁴, John Austin⁵, William Robinson⁶, Ganesh Raghu⁷, Eric Hoffman⁸, John Newell Jr⁸, Jubal Watts Jr⁹, P. Hrudaya Nath⁹, Sushilkumar Sonavane¹⁰, R. Graham Barr⁵ and Elana Bernstein¹, ¹Columbia University, New York, NY, ²University of California, San Diego, San Diego, CA, ³Weill Cornell Medical College, New York, NY, ⁴University of Virginia School of Medicine, Charlottesville, VA, ⁵Columbia University Medical Center, New York, NY, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷University of Washington, Seattle, WA, ⁸University of Iowa, Iowa City, IA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Mayo Clinic, Rochester, MN
Background/Purpose: We previously demonstrated a significant association between serum anti-CCP levels and prevalence of interstitial lung abnormalities (ILA) in community-dwelling adults. A greater number of…
Abstract Number: 1204 • ACR Convergence 2022
An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in Rheumatoid Arthritis: A National, Matched Cohort Study from 2000 to 2019
Tate Johnson¹, Yangyuna Yang², Punyasha Roul³, Windy Alonso², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) predisposes patients to heart failure (HF), a leading cause of hospitalization in the US. While improvements in all-cause and cardiovascular (CVD)…
Abstract Number: 1194 • ACR Convergence 2022
Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease
Jenny Gong¹, Emma Barnboym², megan O'Mara³, Natalie Gurevich³, Maya Mattar⁴, Donald Anthony⁵, Adam Perzynski² and Nora Singer⁶, ¹Case Western School of Medicine, Cleveland, OH, ²The MetroHealth System, Cleveland, OH, ³Cleveland Veteran Affairs Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Patients with autoimmune disease are at increased risk for complications from SARS-CoV-2 infection. We aimed to compare patient perspectives on COVID-19 vaccination among persons…
Abstract Number: 1202 • ACR Convergence 2022
Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019
Palak Shah¹, Ana Arevalo², Rasha Alaameri³, Brinda Basida⁴, Urja Nagadia⁵, Sanket Basida⁵, shobhana Chaudhari⁶ and Monil Majmundar⁷, ¹Metropolitan Hospital Center, New York Medical College, New York, NY, ²University of Chicago, Chicago, IL, ³New York Medical College/ Metropolitan Program, New York, NY, ⁴DMC/Sinai Grace Hospital, Detroit, MI, ⁵University of Missouri, Columbia, MO, ⁶NYC Health and Hospital/Metropolitan Hospital, New York, NY, ⁷University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Vasculitides are characterized by inflammation of vessel walls with reactive damage to mural structures leading to compromise of the lumen. Vasculitides also accelerate atherosclerosis…
Abstract Number: 1215 • ACR Convergence 2022
Identifying a Pain Signature in Classical Ehlers-Danlos Syndrome: Preliminary Results from Questionnaires and Experimental Pain Testing
Marlies Colman, Inge De Wandele, Lies Rombaut, Delfien Syx, Fransiska Malfait and Jessica Van Oosterwijck, Ghent University, Ghent, Belgium
Background/Purpose: Chronic pain is one of the most common complaints of individuals with Ehlers-Danlos syndrome (EDS) and the effects of the existing therapeutical modalities are…
Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…
Abstract Number: 1211 • ACR Convergence 2022
Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need to better…
Abstract Number: 1207 • ACR Convergence 2022
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Huan Meng¹, Steven H Lam², Ho So¹ and Lai-shan Tam³, ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory…
Abstract Number: 1218 • ACR Convergence 2022
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
Philip J Mease¹, Alexis Ogdie², Dimitrios Pappas³, George Reed⁴ and Joel Kremer⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
Abstract Number: 1217 • ACR Convergence 2022
The Problem of Pain in Rheumatology: Clinical Profiles Associated with Concomitant Diagnoses with Chronic Overlapping Pain Conditions
Titilola Falasinnu¹, Yashaar Chaichian² and Julia Simard³, ¹Stanford School of Medicine, Stanford, CA, ²Stanford University, Stanford, CA, ³Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: The chronification of pain is heterogeneous in rheumatology. Chronic overlapping pain conditions (COPCs) such as fibromyalgia, endometriosis, migraine, and back pain may co-occur with…
Abstract Number: 1161 • ACR Convergence 2022
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
Marie-Christin Hoffmann¹, Natalie Fadle¹, Evi Regitz¹, Klaus-Dieter Preuss¹, Marina Zaks², Elisabeth Stöger³, Vincent Zimmer⁴, Philipp Klemm⁵, Gunter Assmann⁶, Bernhard Thurner⁷, Claudia Pföhler⁸, Joerg Thomas Bittenbring¹, Christoph Kessel⁹ and Lorenz Thurner¹, ¹José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, ²Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, ³Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, ⁴Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, ⁵Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ⁶Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, ⁷Department of Pediatrics, Klinikum Kempten, Kempten, Germany, ⁸Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, ⁹Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany
Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].